Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without metastases).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Genentech, Inc.; Rutgers Cancer Institute of New Jersey
• Treatments: Androgens; Ascorbic Acid; Bevacizumab; Bicalutamide; Estrogens, Conjugated (USP); Methyltestosterone

Criteria

Inclusion Criteria:

• History of biopsy documented prostate cancer (any Gleason score)

• Past treatment with prostatectomy with or without salvage prostate/pelvic radiation or primary radiation (external beam or brachytherapy)

• If past prostatectomy, pathologic stage no greater than T1-3, N1, M0

• PSA recurrence with PSAdt < 18 months. There is no minimum PSA for prostatectomy patients. For patients treated with primary radiation therapy PSA should be greater than 2.0 ng/ml

• No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis or CXR

• Prior ADT allowed if < 6 months and testosterone recovered to within 50 units (ng/dl) of normal range

• ECOG Performance status of 0-1

• Absolute neutrophil count of >1,500

• Platelet count > 100,000

• Hg > 8g/dl

• No history of bleeding or thromboses within the last 12 months that required medical intervention

Exclusion Criteria:

• History of cancer within 5 years, other than prostate cancer and non-melanoma skin cancer

• Medical condition requiring concomitant corticosteroids

• Active infection

• Prior chemotherapy allowed if was < 6 cycles and > 6 months prior to study entry

• Documented local recurrence or metastatic prostate cancer

• Inability to comply with study and/or follow-up procedures

• Life expectancy of less than 2 years

• Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study